Crossmark

The efficacy of different biomarkers and endpoints to refine referrals for suspected prostate cancer: the TARGET study (Tiered integrAted tests for eaRly diaGnosis of clinically significant ProstatE Tumours)

Crossref DOI link: https://doi.org/10.1186/s12916-024-03667-7

Published Online: 2024-10-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lophatananon, Artitaya

Muir, Kenneth R.

Gnanapragasam, Vincent J. https://orcid.org/0000-0003-4722-4207
License Information

Text and Data Mining valid from 2024-10-08

Version of Record valid from 2024-10-08
More Information

Article History

Received: 8 April 2024

Accepted: 27 September 2024

First Online: 8 October 2024

Declarations

:

: The study was conducted under UK IRAS ethics REC 03/018. All participants consented to anonymised blood samples and clinical data being used for this study.

: All authors give consent for publishing.

: VJG has previously received a speaker honorarium from Beckman Coulter on biomarkers in prostate cancer prior to the conception of this study. The company also provided free reagents for the PHI assay, however the company was not involved in the design, conduct or reporting of this study nor were involved in drafting or review of this paper. VJG, KM and AL conceived and published the CPG model which is freely available and attracts no fees or royalties of any kind. There are no other competing interests to declare.

Document is current

Any future updates will be listed below